
Opinion|Videos|March 11, 2024
MIRASOL trial and DESTINY-PanTumor02 Trial Overview
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
4
Biktarvy Improves ART Persistence for People With HIV and Mental Health Disorders
5

















































